•
Jun 30, 2020

Allovir Q2 2020 Earnings Report

AlloVir reported financial results for the second quarter ended June 30, 2020.

Key Takeaways

AlloVir reported a net loss of $11.6 million, or $4.43 per share, for the quarter ended June 30, 2020. The company's cash, cash equivalents, and marketable securities totaled $104.5 million as of June 30, 2020. They closed an initial public offering raising $317.7mm in gross proceeds in August.

Research and development expenses were $8.9 million, up from $2.8 million year-over-year.

General and administrative expense was $3.3 million, slightly up from $3.2 million year-over-year.

Cash, cash equivalents, and marketable securities were $104.5 million.

Net loss was $11.6 million, or $4.43 per share, compared to a net loss of $5.3 million, or $5.05 per share, year-over-year.

EPS
-$4.43
Previous year: -$0.126
+3415.6%
R&D Expenses
$8.9M
Previous year: $2.8M
+217.9%
G&A Expenses
$3.3M
Previous year: $3.2M
+3.1%
Cash and Equivalents
$104M

Allovir

Allovir